September 2018

CYTOO enters into Research and Option Agreement with Pfizer to develop a target discovery platform for Duchenne Muscular Dystrophy
06 September 2018
Grenoble, France and NEW YORK, 6 September, 2018   CYTOO and Pfizer Inc. (NYSE: PFE) announced a research collaboration to modify CYTOO’s existing MyoScreenTM platform to enable its potential use as a Duchenne muscular dystrophy (DMD) target discovery platform. DMD is a rare and life-threatening genetic disorder that affects children–approximately 1 in 3,500 to 5,000 boys–and families. It is caused by mutations in the dystrophin gene that results in progressive muscle degeneration and weakness. By the early teens, most individuals with DMD have lost the ability to walk...
Download info read more